Regeneron's Acquisition of Decibel Therapeutics Boosts Gene Therapy Portfolio
Regeneron is acquiring Decibel Therapeutics, a biotech company specializing in gene therapies for hearing loss, in a $109 million deal. The two companies have been collaborating since 2017, and Decibel's lead program focuses on a gene therapy for congenital hearing loss caused by mutations in the otoferlin gene.